Stocktoria
CervoMed Inc. CRVO
CervoMed Inc. (CRVO) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $4.0M at a -673.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.796 |
| Retained earnings / assets | -4.27 |
| EBIT / assets | -1.237 |
| Equity / liabilities | 3.914 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CRVO | CervoMed Inc. | 1/9 | -12.9 | — | — |
| ATAI | AtaiBeckley Inc. | 4/9 | — | — | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | 4/9 | -3.85 | — | — |
| MRKR | Marker Therapeutics, Inc. | 2/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
| PCYN | PROCYON CORP | 3/9 | 3.03 | — | — |
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
FAQ
Is CRVO financially healthy?
CervoMed Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CRVO pay a dividend?
No, CervoMed Inc. does not currently pay a dividend.
How profitable is CRVO?
In FY2025, CervoMed Inc. had a net margin of -673.1% and a return on equity of -148.0%.
Is CRVO overvalued or undervalued?
CervoMed Inc. trades at about 0.0× trailing earnings — below its 10-year norm (10-year range 0.0×–0.0×, median 0.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for CRVO?
The average Wall-Street price target for CervoMed Inc. is $19.50, about 535.2% above the recent price, from 6 analysts.
Is CRVO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CervoMed Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.